Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001
复制标题
DOI：
10.1128/aac.47.5.1681-1688.2003
复制
发表时间：
2003-05-01
影响因子：
4.9
通讯作者：
Sahm, DF
中科院分区：
文献类型：
--
作者：
Karlowsky, JA;Draghi, DC;Sahm, DF
铜绿假单胞菌和鲍曼不动杆菌是从住院患者的临床标本中分离出的最常见的非发酵细菌。 1998年至2001年对美国65个实验室进行的一项监测研究发现，来自住院患者的铜绿假单胞菌分离株中>90%对阿米卡星和哌拉西林-他唑巴坦敏感； 80%至90%的分离株对头孢吡肟、头孢他啶、亚胺培南和美罗培南敏感； 70%至80%的分离株对环丙沙星、庆大霉素、左氧氟沙星和替卡西林克拉维酸敏感。从 1998 年到 2001 年，非重症监护病房 (non-ICU) 住院患者和 ICU 患者的抗菌药物敏感性（百分比）下降幅度最大，环丙沙星（6.1 和 6.5）、左氧氟沙星（6.6 和 3.5）以及头孢他啶（4.8 和 3.3）。 1998 年至 2001 年分别从非 ICU 住院患者和 ICU 患者中分离出的鲍曼不动杆菌结果表明，>90% 的测试分离株对亚胺培南（96.5 和 96.6%）和美罗培南（91.6 和 91.7%）敏感；来自非 ICU 住院患者和 ICU 患者的分离株对阿米卡星和替卡西林克拉维酸敏感的菌株较少（70% 至 80% 敏感）；和
Pseudomonas aeruginosa and Acinetobacter baumannii are the most prevalent nonfermentative bacterial species isolated from clinical specimens of hospitalized patients. A surveillance study of 65 laboratories in the United States from 1998 to 2001 found >90% of isolates of P. aeruginosa from hospitalized patients to be susceptible to amikacin and piperacillin-tazobactam; 80 to 90% of isolates to be susceptible to cefepime, ceftazidime, imipenem, and meropenem; and 70 to 80% of isolates to be susceptible to ciprofloxacin, gentamicin, levofloxacin, and ticarcillin-clavulanate. From 1998 to 2001, decreases in antimicrobial susceptibility (percents) among non-intensive-care-unit (non-ICU) inpatients and ICU patients, respectively, were greatest for ciprofloxacin (6.1 and 6.5), levofloxacin (6.6 and 3.5), and ceftazidime (4.8 and 3.3). Combined 1998 to 2001 results for A. baumannii isolated from non-ICU inpatients and ICU patients, respectively, demonstrated that >90% of isolates tested were susceptible to imipenem (96.5 and 96.6%) and meropenem (91.6 and 91.7%); fewer isolates from both non-ICU inpatients and ICU patients were susceptible to amikacin and ticarcillin-clavulanate (70 to 80% susceptible); and